Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02388659 · ClinicalTrials.gov registry record
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas
A clinical trial, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 142
- Enrollment target
NCT02388659: Completed study, sponsored by University of Texas Southwestern Medical Center.
NCT02388659 is a clinical trial that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 142 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02388659 has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 142 participants
- Enrollment target
Study Summary
The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in IDH mutated gliomas and IDH wild type gliomas.
Primary Outcome
The investigators anticipate the study will provide significant value in many aspects of management of gliomas. 3D evaluation of the cancer biomarkers using MRSI will provide biological insights for making the diagnosis of gliomas, tracking of infiltrative cells during follow up, and determining response to treatment.
Interventions
- DEVICE 3 Tesla scanning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2014-02 |
| Est. Completion | 2021-12-31 |
What the finished NCT02388659 record still lists
NCT02388659 is an observational study that tracks outcomes without assigning an intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which 3 Tesla scanning is the first listed.
NCT02388659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02388659 about?
NCT02388659 is a clinical study titled "Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas". The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in IDH mutated gliomas and IDH wild type gliomas.
What is the current status of trial NCT02388659?
This trial is currently completed. The enrollment target is 142 participants. The study started on 2014-02. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02388659?
The interventions under investigation include: 3 Tesla scanning (DEVICE).
Who is sponsoring clinical trial NCT02388659?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia